AstraZeneca
AZN
Performance
About AstraZeneca
AstraZeneca is a global science-led biopharmaceutical company that develops innovative medicines used by patients worldwide. It focuses on research-based discovery and development across multiple therapy areas, including oncology, cardiovascular, renal and metabolism, respiratory and immunology, vaccines, and rare diseases. The company emphasizes scientific collaboration and translational medicine to deliver targeted therapies and improve global health. Headquartered with a strong presence in the UK and collaborating worldwide, AstraZeneca operates through a global network of R&D centers and manufacturing facilities.
Recent News
Asian Marco Initial Thoughts: US/Iran Stand-Off the Main Focus; Oil Price Rising. Warsh Nomination for Fed Chair to Be Voted on Wednesday, Central Banks Rate Decisions in Focus This Week.
Innate Pharma to Participate in the Kempen Life Sciences Conference
FDA Clears AstraZeneca‑Daiichi Sankyo’s Datroway for Metastatic Triple‑Negative Breast Cancer
Fleet Operators Rally Against EV Policy Pushback in EU
ASCO26: AZ Triplet Makes Waves in Frontline Liver Cancer
STAT+: Pharmalittle: We’re Reading About FDA Seeking More Data on a Lilly Obesity Pill, a Pharma 340B Win, and More
FDA ODAC Backs AstraZeneca’s Truqap Combo for PTEN‑deficient Prostate Cancer
Biotech in 2025: A Retrospective
FDA Launches Real-Time Clinical Trials Pilot to Cut Drug Development Timelines
Dizal Breaks New Ground for EGFR Drugs in Lung Cancer
340B Claims Data Requirements Put Hospital Discounts Under Stress
NYAG Takes Action Against Public Company for Approving Insider 10b5-1 Plan
Health Care Roundup: Market Talk
Prasugrel After PCI Outperforms Other Common Antiplatelet Drugs
AbbVie Sinks Talons Into KRAS with Right to Buy Kestrel for up to $1.45B
Pfizer Deals Extend Patent Life for a Top-Selling Rare Disease Drug
TerraPower Commits $450M to Build Radioisotope Production Plant
Breast Cancer Treatments Heat Up: Six Therapies Poised to Transform Patient Outcomes
Terremoto Wins $108m in Series C to Drive Cancer and Rare Disease Programmes
FDA Launches Real‑Time Clinical Trials to Accelerate Drug Development
AstraZeneca, Daiichi Sankyo Win EU CHMP Nod for Enhertu in HER2 Tumors
Q3 Results Today Live: M&M, Divi’s Lab, Ashok Leyland, Lenskart, LG Electronics, Godrej, Patanjali Foods, AstraZeneca to Announce Q3 Results, Titan, Apollo Hospitals, Britannia Shares Gain, P N Gadgil & Grasim Shares in Red
AstraZeneca PLC (AZN) Stock Falls as FDA Panel Votes Against New Cancer Drug
GSK Functionally Cures Hepatitis B, Lilly's $3.8B Vaccine Pivot, and Base Editing Holds for 18 Months – This Week in Biotech #102
Boston Properties Posts Q4 2025 Earnings, Flags Office Market Headwinds
AstraZeneca Reports the US FDA Approval of Baxfendy (Baxdrostat) To Treat Hard-to-Control Hypertension
Cooley Wins Eight LBG Life Sciences EMEA Awards
AstraZeneca and Joshua Jackson Partner to Encourage Fans to Get Body Checked Against Cancer
The Road Ahead—What’s Next for Host Cell Protein Analytics?
AstraZeneca CEO Hails NHS Drug Price Deal but Keeps Pause on £200m UK Investment
AstraZeneca Reports the P-III (I CAN) Trial Data on Ultomiris for IgA Nephropathy
GSK Reports Promising Early Results in Ovarian and Womb Cancer Drug Trial
Hacker Group LAPSUS$ Claims Alleged AstraZeneca Data Breach
AstraZeneca and Daiichi Sankyo Secure Earlier‑Line Enhertu Approvals in South Korea
Brepocitinib Approval May Be ‘Highlight of the Derm-Rheum World’
Apple's Expanding Enterprise Footprint to Boost Sales: What's Ahead?
AstraZeneca Leads Big Pharma’s AI Clinical Trials Revolution with Real-World Patient Impact
ASCO26: Solid Tumour Data Readouts Outline Merck & Co’s Oncology Prowess
JCR Pharmaceuticals Highlights Preclinical CNS Gene Therapy Data for JUST-AAV Platform at ASGCT 2026
Immunotherapy Drug Helps Bladder Cancer Patients Avoid Major Organ Removal
In the Clinic for May 13, 2026
HER2’s Digital Rebirth Is Unlocking the Full Potential of ADCs
EU Starts Review of First-Line Enhertu for Breast Cancer
Lipocine's Postpartum Depression Drug Fails; AstraZeneca Claims Liver Cancer Win
A Study in Regulatory Conservatism versus Clinical Innovation
Stock Market Concentration: Is It Dangerous and Should Investors Be Worried?
How APAC Should Deploy AI to Find Hidden Lung Cancers
Pfizer’s Oncology Sales Poised for Growth Ahead of Q1 Earnings
Niowave, Fresh From Novartis Deal, Starts Building $75M Radioisotope Plant
Celcuity Breast Cancer Drug Misses ‘Lofty’ Expectations in ASCO-Spotlighted Trial
Recent Deals
AstraZeneca Acquires FibroGen China From Kyntra Bio
Kyntra Bio Completes Sale of FibroGen China to AstraZeneca
AstraZeneca Pays $630M to Acquire Full Control of AbelZeta's CAR‑T Therapy C‑CAR031
AstraZeneca Signs $1.2B Upfront Deal with CSPC for Obesity Assets
Syneron Bio Closes $150M Series B Funding Round